[A randomized controlled study of the VKORC1 and CYP2C9 genotypes in guiding warfarin therapy for pulmonary thromboembolism].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

Volumn 36, Issue 12, 2013, Pages 950-953

  Li, Jie ^a   Liu, Shuang ^a   Yang, Jing hua ^a   Guo, Wei ^a   Wang, Zeng zhi ^a   Chen, Yong ^a   Wang, Sheng hao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN; WARFARIN;

AGED; ALGORITHM; ARTICLE; ASIAN; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; GENETICS; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PULMONARY EMBOLISM; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84903521465     PISSN: 10010939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)